Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
Rang in Aktien #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2023-05-22
Marktkapitalisierung
$10.03K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel NuGenerex Immuno-Oncology, Inc. (NUGX)

Kategorie

Dividendenrendite-Verlauf für NuGenerex Immuno-Oncology, Inc. (NUGX)
Dividendenrendite (TTM) von NuGenerex Immuno-Oncology, Inc. (Aktienkürzel: NUGX) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für NuGenerex Immuno-Oncology, Inc. (NUGX) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber